|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Romond EH, Perez EA, Bryant J, et al:
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mahamodhossen YA, Liu W and Rong-Rong Z:
Triple-negative breast cancer: new perspectives for novel
therapies. Med Oncol. 30:6532013. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar
|
|
8.
|
Schneider BP, Winer EP, Foulkes WD, et al:
Triple-negative breast cancer: risk factors to potential targets.
Clin Cancer Res. 14:8010–8018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bosch A, Eroles P, Zaragoza R, Viña JR and
Lluch A: Triple-negative breast cancer: molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Balko JM, Cook RS, Vaught DB, et al:
Profiling of residual breast cancers after neoadjuvant chemotherapy
identifies DUSP4 deficiency as a mechanism of drug resistance. Nat
Med. 18:1052–1059. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ur-Rehman S, Gao Q, Mitsopoulos C and
Zvelebil M: ROCK: a resource for integrative breast cancer data
analysis. Breast Cancer Res Treat. 139:907–921. 2013.PubMed/NCBI
|
|
12.
|
van de Vijver MJ, He YD, van’t Veer LJ, et
al: A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med. 347:1999–2009. 2002.
|
|
13.
|
Chin K, DeVries S, Fridlyand J, et al:
Genomic and transcriptional aberrations linked to breast cancer
pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Butte A: The use and analysis of
microarray data. Nat Rev Drug Discov. 1:951–960. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Han Y, Huang H, Xiao Z, et al: Integrated
analysis of gene expression profiles associated with response of
platinum/paclitaxel-based treatment in epithelial ovarian cancer.
PLoS One. 7:e527452012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Konstantinopoulos PA, Cannistra SA,
Fountzilas H, et al: Integrated analysis of multiple microarray
datasets identifies a reproducible survival predictor in ovarian
cancer. PLoS One. 6:e182022011. View Article : Google Scholar
|
|
17.
|
Richardson AL, Wang ZC, De Nicolo A, et
al: X chromosomal abnormalities in basal-like human breast cancer.
Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Brown MP, Grundy WN, Lin D, et al:
Knowledge-based analysis of microarray gene expression data by
using support vector machines. Proc Natl Acad Sci USA. 97:262–267.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Perreard L, Fan C, Quackenbush JF, et al:
Classification and risk stratification of invasive breast
carcinomas using a real-time quantitative RT-PCR assay. Breast
Cancer Res. 8:R232006. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hu Z, Fan C, Oh DS, et al: The molecular
portraits of breast tumors are conserved across microarray
platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer - current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Rouzier R, Perou CM, Symmans WF, et al:
Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Vogel CL, Cobleigh MA, Tripathy D, et al:
Efficacy and safety of trastuzumab as a single agent in first-line
treatment of HER2-overexpressing metastatic breast cancer. J Clin
Oncol. 20:719–726. 2002. View Article : Google Scholar
|
|
24.
|
Hinnis AR, Luckett JC and Walker RA:
Survivin is an independent predictor of short-term survival in poor
prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Span PN, Tjan-Heijnen VC, Heuvel JJ, de
Kok JB, Foekens JA and Sweep FC: Do the survivin (BIRC5) splice
variants modulate or add to the prognostic value of total survivin
in breast cancer? Clin Chem. 52:1693–1700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Islam A, Kageyama H, Takada N, et al: High
expression of Survivin, mapped to 17q25, is significantly
associated with poor prognostic factors and promotes cell survival
in human neuroblastoma. Oncogene. 19:617–623. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Regnier V, Vagnarelli P, Fukagawa T, et
al: CENP-A is required for accurate chromosome segregation and
sustained kinetochore association of BubR1. Mol Cell Biol.
25:3967–3981. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Amato A, Schillaci T, Lentini L and Di
Leonardo A: CENPA overexpression promotes genome instability in
pRb-depleted human cells. Mol Cancer. 8:1192009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Archangelo LF, Greif PA, Maucuer A, et al:
The CATS (FAM64A) protein is a substrate of the Kinase Interacting
Stathmin (KIS). Biochim Biophys Acta. 1833:1269–1279. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Takagi K, Miki Y, Shibahara Y, et al: BUB1
immunolocalization in breast carcinoma: its nuclear localization as
a potent prognostic factor of the patients. Horm Cancer. 4:92–102.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Li L, Xu DB, Zhao XL and Hao TY:
Combination analysis of Bub1 and Mad2 expression in endometrial
cancer: act as a prognostic factor in endometrial cancer. Arch
Gynecol Obstet. 288:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Hegyi K and Mehes G: Mitotic failures in
cancer: Aurora B kinase and its potential role in the development
of aneuploidy. Pathol Oncol Res. 18:761–769. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Takeshita M, Koga T, Takayama K, et al:
Aurora-B overexpression is correlated with aneuploidy and poor
prognosis in non-small cell lung cancer. Lung Cancer. 80:85–90.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Tchatchou S, Wirtenberger M, Hemminki K,
et al: Aurora kinases A and B and familial breast cancer risk.
Cancer Lett. 247:266–272. 2007. View Article : Google Scholar : PubMed/NCBI
|
